Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity

Mathematical Biosciences

Volumn 184, Issue 2, 2003, Pages 165-186

  Huang, Yangxin ^a   Rosenkranz, Susan L ^a   Wu, Hulin ^a  

^a FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

Adherence; Antiviral therapy; Clinical trial simulation; Drug resistance; HIV; Pharmacokinetics

Indexed keywords

ABSORPTION; DRUG THERAPY; ENZYME INHIBITION; PHARMACOKINETICS;

ANTIRETROVIRAL THERAPIES;

VIRUSES;

ANTIRETROVIRUS AGENT; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; MODELING;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; COMPARTMENT MODEL; COMPUTER SIMULATION; DISEASE SIMULATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; PATIENT COMPLIANCE; PHENOTYPE; PROTEINASE INHIBITION; TIME; TREATMENT FAILURE; VIRUS DETECTION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0037696057     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-5564(03)00058-0     Document Type: Article

References (43)

1. S. Merrill, Modeling the interaction of HIV with the cells of the immune system, in: Mathematical and Statistical Approaches to AIDS Epidemiology, Lecture Notes in Biomathematics, vol. 83, Springer, New York, 1989.
2. + T-cell infection by HIV and some Monte Carlo studies, Math. Biosci. 147 (1998) 173.
3. R.M. Ribeiro, S. Bonhoeffer, A stochastic model for primary HIV infection: optimal timing of the therapy, AIDS 13 (1999) 351.
4. R.M. Ribeiro, S. Bonhoeffer, Production of resistant HIV mutants during antiretroviral therapy, Proc. Natl. Acad. Sci. USA 97 (2000) 7681.
5. R.M. Anderson, R.M. May, Epidemiology parameters of HIV transmission, Nature 333 (1988) 514.
6. A.A. Ding, H. Wu, Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics, Math. Biosci. 160 (1999) 63.
7. + T-cells subpopulations, J. Theoret. Biol. 170 (1994) 367.
8. T.B. Kepler, A.S. Perelson, Drug concentration heterogeneity facilitates the evolution of drug resistance, Proc. Natl. Acad. Sci. USA 95 (1998) 11514.
9. M.A. Nowak, S. Bonhoeffer, G.M. Shaw, R.M. May, Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations, J. Theoret. Biol. 184 (1997) 203.
10. + T cells, Math. Biosci. 114 (1993) 81.
11. A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science 271 (1996) 1582.
12. A.S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, D.D. Ho, Decay characteristics of HIV-1-infected compartments during combination therapy, Nature 387 (1997) 188.
13. A.S. Perelson, P.W. Nelson, Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev. 41 (1) (1999) 3.
14. L.M. Wahl, M.A. Nowak, Adherence and resistance: predictions for therapy outcome, Proc. Roy. Soc., Bio. 267 (2000) 835.
15. H. Wu, D.R. Kuritzkes, M.S. Clair, H. Kessler, E. Connick, A. Landay, M. Heath-Chiozzi, F. Rousseau, L. Fox, J. Spritzler, J.M. Leonard, D.R. McClernon, M.M. Lederman, Interpatient variation of viral dynamics in HIV-1 infection: modeling results of AIDS clinical trials group protocol 315, in: The International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, Abstract 99 (1997).
16. H. Wu, A.A. Ding, Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials, Biometrics 55 (1999) 410.
17. H. Wu, D.R. Kuritzkes, D.R. McClernon, et al., Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints, J. Infect. Dis. 179 (4) (1999) 799.
18. A.A. Ding, H. Wu, Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models, Biostatistics 2 (2001) 13.
19. S. Bonhoeffer, M.A. Nowak, Pre-existence and emergence of drug resistance in HIV-1 infection, Proc. Roy. Soc., Bio. 264 (1997) 631.
20. S.D.W. Frost, A.R. Mclean, Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection, AIDS 8 (1994) 323.
21. A.R. Mclean, V.C. Emery, A. Webster, P.D. Griffiths, Population dynamics of HIV within an individual after treatment with zidovudine, AIDS 5 (1991) 485.
22. A.R. Mclean, M.A. Nowak, Competition between zidovudine sensative and resistant strains of HIV, AIDS 6 (1992) 71.
23. M.A. Nowak et al., Antigenic diversity thresholds and the development of AIDS, Science 254 (1991) 963.
24. X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, M.S. Saag, G.M. Shaw, Viral dynamics in human immunodeficiency virus type 1 infection, Nature 373 (1995) 117.
25. C.N. Verme, T.M. Ludden, W.A. Clementi, S.C. Harris, Pharmacokinetics of quinidine in male patients: a population analysis, Clin. Pharmacokinet. 22 (1992) 468.
26. M. Davidian, D.M. Giltinan, Nonlinear Models for Repeated Measurement Data, Chapman and Hall, New York, 1995.
27. Abbott Laboratories, Product Information. Website: http://www.norvir.com/hiv/hiv0044.htm.
28. GlaxoSmithKline, Product Information. Website: http://www.gsk.com/products/prescriptionmedicines.shtml.
29. A. Molla et al., Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nature Med. 2 (1996) 760.
30. M.A. Wainberg et al., Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase, AIDS 10 (Suppl.) (1996) S3.
31. S. Bonhoeffer, M. Lipsitch, B.R. Levin, Evaluating treatment protocols to prevent antibiotic resistance, Proc. Natl. Acad. Sci. USA 94 (1997) 12106.
32. M. Rowland, T.N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 3rd Ed., Williams & Wilkins, Baltimore, MD, 1995.
33. L.B. Sheiner, Modeling pharmacodynamics: parametric and nonparametric approaches, in: M. Rowland et al. (Eds.), Variability in Drug Therapy: Description, Estimation, and Control, Raven, New York, 1985, p. 139.
34. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, M. Markowitz, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature 373 (1995) 123.
35. M.A. Nowak, R.M. May, Virus dynamics: mathematical principles of immunology and virology, Oxford University, Oxford, 2000.
36. D.S. Callaway, A.S. Perelson, HIV-1 infection and low steady state viral loads, Bull. Math. Biol. 64 (2002) 29.
37. R.E. Chaisson, When to start antiretroviral therapy? in: 9th Conference on Retroviruses and Opportunistic Infections, Abstract S17 (Session 21), Seattle, WA, February 24-28, 2002.
38. A.S. Perelson, Modeling the interaction of the immune system with HIV, in: C. Castillo-Chavez (Ed.), Mathematical and Statistical Approaches to AIDS Epidemiology, Lecture Notes in Biomathematics, vol. 83, Springer, New York, 1989.
39. C.L. Besch, Compliance in clinical trials, AIDS 9 (1995) 1.
40. J.R. Ickovics, A.W. Meisler, Adherence in AIDS clinical trial: a framework for clinical research and clinical care, J. Clin. Epidemiol. 50 (1997) 385.
41. N.H.G. Holford, H.C. Kimko, J.P.R. Monteleone, C.C. Peck, Simulation of clinical trials, Ann. Rev. Pharmacol. Toxicol. 40 (2000) 209.
42. M. Pfister, L. Labbé, S.M. Hammer, J. Mellors, K.K. Bennett, S.L. Rosenkranz, L.B. Sheiner and the AIDS Clinical Trial Group Protocol 398 Investigators, Population Pharmacokinetics/Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir in AACTG Study 398. Under review at Antimicrobial Agents and Chemotherapy.
43. H. Kastrissios, J.R. Suárez, D. Katzenstein, P. Girard, L.B. Sheiner, T.F. Blaschke, Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial, AIDS 12 (1998) 2295.